Opiant Pharmaceuticals (NASDAQ:OPNT) and Adamant DRI Processing&Minerals Group (OTCMKTS:ADMG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Earnings & Valuation
This table compares Opiant Pharmaceuticals and Adamant DRI Processing&Minerals Group’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$13.98 million||3.72||-$21.19 million||($7.10)||-1.86|
|Adamant DRI Processing&Minerals Group||$50,000.00||12.23||$21.25 million||N/A||N/A|
Adamant DRI Processing&Minerals Group has lower revenue, but higher earnings than Opiant Pharmaceuticals.
Institutional & Insider Ownership
20.1% of Opiant Pharmaceuticals shares are owned by institutional investors. 30.9% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Opiant Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Adamant DRI Processing&Minerals Group has a beta of 5.1, meaning that its stock price is 410% more volatile than the S&P 500.
This table compares Opiant Pharmaceuticals and Adamant DRI Processing&Minerals Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamant DRI Processing&Minerals Group||N/A||-5.67%||3.52%|
This is a summary of current recommendations and price targets for Opiant Pharmaceuticals and Adamant DRI Processing&Minerals Group, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamant DRI Processing&Minerals Group||0||0||0||0||N/A|
Opiant Pharmaceuticals presently has a consensus price target of $42.00, suggesting a potential upside of 217.22%. Given Opiant Pharmaceuticals’ higher possible upside, analysts clearly believe Opiant Pharmaceuticals is more favorable than Adamant DRI Processing&Minerals Group.
Adamant DRI Processing&Minerals Group beats Opiant Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
About Adamant DRI Processing&Minerals Group
Adamant DRI Processing and Minerals Group focuses on mining, processing, producing, and selling direct reduced iron feed stock for the steel industry in the People's Republic of China. The company owns an iron ore concentrate production line on the Zhuolu Mine, which is located in Zhuolu County, Hebei Province. It also intends to produce direct reduced iron using advanced reduction rotary kiln technology with iron sand as the principal raw material. The company is based in Zhangjiakou, the People's Republic of China.
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.